Brian Sylvester spoke with InsideHealthPolicy about concerns that the FDA may lack the resources to implement its proposed overhaul of the Generally Recognized as Safe (GRAS) framework, which would require companies to notify the agency of safety determinations for food ingredients. Brian commented on whether the FDA has fully accounted for the potentially significant volume of submissions involving flavors, enzymes, processing aids and other ingredients. He warned that mandatory submissions could create backlogs, increase costs and disrupt product development, stating “It’s not clear to me that the FDA appreciates the actual volume and the resources that it would require.”
Read the full article.
